Telos PGX Partners with Skilled Nursing Facilities to Elevate Resident-Centered Care through Advanced Pharmacogenetic Testing

Telos PGX collaborates with Texas-based Skilled Nursing Facilities, delivering cutting-edge pharmacogenetic testing to improve patient outcomes and meet quality metrics.

Addison, Texas, United States – September 8, 2024 —

Pharmacogenetics Driving Personalized Care in Skilled Nursing Facilities

Telos PGX, a pioneering pharmacogenetic laboratory based in Addison, Texas, is forging a transformative partnership with Skilled Nursing Facilities (SNFs) across the state. As SNFs face increasing pressure to meet CMS (Centers for Medicare & Medicaid Services) and HHSC (Texas Health and Human Services Commission) quality metrics, Telos PGX’s innovative genetic testing is poised to play a key role in improving resident-centered care.

By focusing on personalized medicine through pharmacogenetic testing, Telos PGX is helping these facilities optimize care, reduce adverse drug reactions, and enhance therapeutic outcomes—factors crucial in addressing the Quality Incentive Payment Program (QIPP) metrics. Specifically, the initiative supports facilities in reducing the prescription of antipsychotics and documenting residents’ ability to move freely, directly aligning with QIPP’s goals.

Under the visionary leadership of founder and CEO D.J. Hart, Telos PGX is establishing itself as a vital partner for SNFs in Texas, helping them navigate the challenges of regulatory compliance while prioritizing the well-being of their residents.

Meeting QIPP Metrics through Personalized Medicine

The Quality Incentive Payment Program (QIPP) has set stringent metrics to improve the quality of care in Skilled Nursing Facilities. Two major components of these metrics include deprescribing antipsychotics and monitoring residents’ freedom of movement. Telos PGX’s pharmacogenetic testing offers an innovative solution that directly supports these goals by helping clinicians tailor medication regimens based on a resident’s unique genetic makeup.

D.J. Hart, CEO of Telos PGX, emphasizes the importance of personalized medicine in achieving these outcomes: “Operators participating in programs such as QIPP align well with Telos PGX as they are truly resident-centered. With the enforcement of the metrics specifically related to deprescribing antipsychotics and documenting a resident’s decline to move freely, PGX testing makes sense.”

By leveraging pharmacogenetic data, SNFs can better understand how residents metabolize medications, allowing for more precise prescribing decisions. This not only enhances the efficacy of treatments but also minimizes the risk of adverse drug reactions—an important consideration in the care of elderly populations.

The Power of Genetic Insights in Long-Term Care

Pharmacogenetic testing provides clinicians with a blueprint of how a patient’s genetics affect their response to medications. For residents in SNFs, this testing is invaluable. The elderly population is particularly vulnerable to adverse drug reactions, which can lead to unnecessary hospitalizations, increased healthcare costs, and a decline in quality of life.

Telos PGX’s testing identifies specific genetic variants that influence how medications are metabolized, absorbed, and processed. This allows healthcare providers to adjust dosages or select alternative medications based on the patient’s genetic profile, reducing the trial-and-error approach often seen in traditional prescribing.

“Pharmacogenetic testing offers clinicians actionable insights that are essential for delivering personalized care,” Hart explained. “By understanding a resident’s genetic profile, we can ensure that the treatments we provide are not only safe but also effective. This is the future of medicine, and we are proud to be at the forefront of it.”

A Key Partner in Navigating Regulatory Challenges

The healthcare industry, particularly in long-term care settings, is becoming increasingly regulated. With programs like QIPP driving facilities to improve outcomes, the need for accurate and personalized care is more critical than ever. Telos PGX’s pharmacogenetic testing is a powerful tool for SNFs striving to meet these benchmarks.

By reducing the need for antipsychotics and improving overall patient care through personalized treatment plans, Telos PGX enables SNFs to demonstrate their commitment to resident-centered care. This not only benefits the residents themselves but also positions facilities to receive performance-based incentives through programs like QIPP.

“At Telos PGX, we understand the unique challenges that Skilled Nursing Facilities face,” Hart said. “Our goal is to provide them with the tools and insights they need to meet regulatory requirements while ensuring that their residents receive the best possible care.”

Innovating Care in a Stagnant Market

Telos PGX’s specialization in pharmacogenetics sets it apart in a market that has remained largely stagnant for years. While other laboratories offer a variety of tests, Telos PGX is one of the few laboratories in the country to focus exclusively on pharmacogenetics. This singular focus allows the company to offer unparalleled expertise and cutting-edge technology that directly benefits its clients.

As part of its commitment to advancing personalized medicine, Telos PGX continuously updates its testing panels in line with the latest FDA-approved drug-gene interactions. This ensures that its clients always have access to the most up-to-date and relevant information when making critical healthcare decisions.

“Being one of the only laboratories in the nation to specialize solely in pharmacogenetics allows us to stay at the forefront of this rapidly evolving field,” said Hart. “We are dedicated to delivering the highest level of precision and care to our clients, helping them provide the best possible outcomes for their residents.”

Empowering Healthcare Providers through Education and Support

In addition to offering advanced pharmacogenetic testing, Telos PGX is dedicated to supporting healthcare providers through education and outreach. The company offers resources and guidance to help clinicians understand how to incorporate pharmacogenetic insights into their practice, ultimately leading to improved patient care.

Telos PGX believes that the future of healthcare lies in the integration of genetic data into everyday medical decisions. By partnering with Skilled Nursing Facilities, the company aims to make personalized medicine accessible and impactful, fostering a healthcare environment where treatments are tailored to the individual needs of each patient.

“Education is a key component of what we do,” Hart noted. “We don’t just provide testing; we empower healthcare providers with the knowledge they need to use this information effectively. Our goal is to drive a shift in how healthcare is delivered, making it more personalized, more effective, and ultimately better for the patient.”

About Telos PGX

Telos PGX is a leading pharmacogenetic laboratory based in Addison, Texas, specializing in genetic testing that informs personalized medicine. Focused on improving patient outcomes through precise medication management, Telos PGX serves healthcare providers, Skilled Nursing Facilities, and Medicare beneficiaries across Texas. The laboratory is committed to staying at the forefront of pharmacogenetic research and technology, delivering actionable insights that enhance therapeutic outcomes and reduce adverse drug reactions.

For more information, visit www.telospgx.com or follow Telos PGX on Facebook and LinkedIn.

Media Contact
Telos PGX
Website: www.telospgx.com
Facebook
LinkedIn

Contact Info:
Name: DJ Hart
Email: Send Email
Organization: Telos PGX
Website: https://telospgx.com/

Release ID: 89140589

If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.